ORGO Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Revenue: $150.5 million, up 31% year-over-year and 49% sequentially, exceeding guidance of $130 million to $145 million.

Advanced Wound Care Revenue: $141.5 million, a 31% increase year-over-year.

Surgical & Sports Medicine Revenue: $9 million, up 25% year-over-year.

Gross Profit: $114.2 million, representing 76% of net product revenue (down from 77% the previous year).

Operating Expenses: $130.1 million, up 19% year-over-year.

Operating Income: $20.7 million, compared to $6.2 million last year.

GAAP Net Income: $21.6 million, up from $12.3 million.

Adjusted EBITDA: $30.1 million, compared to $13.4 million last year.

Cash Position: $64.4 million in cash and equivalents, down from $136.2 million at the end of 2024.

2Strategic Updates and Business Highlights

Strong growth in Advanced Wound Care and Surgical & Sports Medicine products attributed to effective execution and customer relationships.

The final Medicare physician fee schedule for 2026 was announced, which includes significant changes for skin substitutes, potentially enhancing reimbursement rates for PMA products.

The company is positioned to leverage its strong brand equity and clinical efficacy to capture market share as competitors face pricing pressures.

Updates on the ReNu program indicate a favorable safety profile despite the second Phase III trial not achieving statistical significance for its primary endpoint. The FDA granted ReNu RMAT designation, and a meeting is scheduled for December to discuss the submission for a biologic license application.

3Forward Guidance and Outlook

2025 Revenue Guidance: Updated to $500 million to $525 million, reflecting a year-over-year increase of 4% to 9%.

Advanced Wound Care Revenue Guidance: Expected between $470 million and $490 million, a 4% to 8% increase.

Surgical & Sports Medicine Revenue Guidance: Expected between $30 million and $35 million, a 6% to 23% increase.

Profitability Guidance: GAAP net income projected between $8.6 million and $25.4 million, with adjusted EBITDA guidance raised to $45.5 million to $68.3 million.

4Bad News, Challenges, or Points of Concern

The second Phase III trial for ReNu did not meet its primary endpoint, which could impact future approval timelines and market expectations.

The company missed the November 1 submission deadline for new data for LCD coverage consideration for PuraPly AM, which may delay reimbursement opportunities.

Operating expenses increased significantly, raising concerns about cost management as the company invests in growth.

ASPs (average selling prices) across the market are expected to decline, which may pressure margins despite the anticipated growth in revenue.

5Notable Q&A Insights

Management indicated that early signs of physician behavior change are emerging in response to the new fee schedule, with some movement towards products on the approved LCD list.

The company is confident in its ability to generate awareness and drive sales as competitors exit the market due to pricing pressures.

There is cautious optimism regarding the ReNu timeline, with a potential 2-month delay in filing expected, though the company aims to maintain its original timeline if possible.

The competitive landscape is shifting, with over 200 products losing coverage under the new LCD, which could benefit Organogenesis as it has multiple products on the covered list.